|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT01266785 |
|
Date of registration:
|
23/12/2010 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Infliximab, Regulatory T Cells, IL2 and Crohn's Disease
|
|
Scientific title:
|
Analysis of Relationship Between Infliximab Treatment Response, Regulatory T Cells, and Interleukin-2 in Crohn's Disease |
|
Date of first enrolment:
|
December 2010 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
https://clinicaltrials.gov/show/NCT01266785 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Zili Zhange, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Oregon Health and Science University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Newly diagnosed or exacerbating CD (Moderate to severe CD).
- The diagnosis of moderate to severe CD will be confirmed by previous endoscopy and
biopsy.
- Have the capacity to understand and sign an informed consent form.
Age minimum:
18 Years
Age maximum:
70 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Crohn's Disease
|
|
Intervention(s)
|
|
Drug: Infliximab
|
|
Primary Outcome(s)
|
|
Changes of IL-2 and Treg cell levels
[Time Frame: 1 year]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|